Acadia Pharma (ACAD) Misses Q1 EPS by 3c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $27.29 -0.58%
EPS Growth %: -52.4%
Financial Fact:
Collaborative revenues: 5.27M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: -52.4%
Financial Fact:
Collaborative revenues: 5.27M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q1 EPS of $0.02, $0.03 worse than the analyst estimate of $0.05. Revenue for the quarter came in at $268.06 million versus the consensus estimate of $280.92 million.
GUIDANCE:
Acadia Pharma sees FY2026 revenue of $1.22-1.28 billion, versus the consensus of $1.23 billion.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- U.S. and Denmark close in on a Greenland deal - Reuters
- Enablence closes C$25M private placement with Collingwood Investments
- Teva shares Phase 3 data on once-monthly schizophrenia injection
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
